Related Experiment Videos
Implications of doxazosin therapy on risk of coronary heart disease
1Department of Medicine, Ostra Hospital, Göteborg, Sweden.
Insights
Antihypertensive treatments reduce some risks but not coronary heart disease. Doxazosin, an alpha 1-inhibitor, may improve outcomes due to its effective blood pressure control and favorable lipid effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Antihypertensive treatment reduces mortality and cardiovascular morbidity.
- However, treated patients still face higher risks, especially for coronary heart disease (CHD).
- Previous treatments may be suboptimal due to inadequate blood pressure control or adverse effects on lipoproteins.
Purpose of the Study:
- To evaluate the potential of doxazosin, a selective alpha 1-inhibitor, in improving cardiovascular outcomes.
- To assess if doxazosin's dual action (antihypertensive and lipid-modifying) offers advantages over existing treatments.
Main Methods:
- The study focuses on the pharmacological properties of doxazosin.
- It analyzes the impact of selective alpha 1-inhibition on blood pressure and serum lipoproteins.
Main Results:
- Doxazosin demonstrates effective antihypertensive action.
- It also exhibits a favorable effect on serum lipid profiles.
- These combined effects suggest a potential benefit for CHD risk reduction.
Conclusions:
- Doxazosin's dual efficacy in lowering blood pressure and improving lipid profiles may enhance its effectiveness in managing hypertension.
- It holds promise for positively impacting coronary heart disease risk, potentially outperforming older antihypertensive agents.
Abstract:
Antihypertensive treatment is known to reduce mortality in severe hypertension and cardiovascular morbidity in mild and moderately severe hypertension, for example, from stroke and left ventricular failure. However, treated hypertensive patients still have significantly higher mortality and morbidity than matched control subjects. In particular, risk of coronary heart disease is affected little by antihypertensive treatment. There may be several explanations for these less than optimal results. For example, blood pressure may not have been brought down to strictly normotensive levels or an antihypertensive agent, which adversely affects serum lipoproteins, may have been used, thereby offsetting the intended therapeutic effect. Doxazosin, a new selective alpha 1-inhibitor, offers both effective antihypertensive action and a favorable lipid effect. Both of these effects could have a positive impact on risk of coronary heart disease and therefore may prove to be more effective than previously used antihypertensive treatments.